University of Copenhagen

Evosep unveiled the Evosep Eno, a high-throughput separation platform that can analyze over 500 samples per day and identify close to 7,000 proteins with 40% improved performance.

• Ousia Pharma has secured significant seed financing from Omega Funds to advance its dual-incretin-NMDA receptor antagonist conjugate for obesity treatment through preclinical and early clinical development. • The company's innovative approach leverages incretin hormone analogues to deliver small-molecule neuroplasticity modulators directly to brain appetite control centers, potentially addressing limitations of current GLP-1 therapies. • Industry veterans from AstraZeneca, including Prof. Sir Mene Pangalos and Dr. Elisabeth Björk, will join Ousia's Board of Directors, bringing extensive experience in cardiometabolic drug development.

Glofitamab combined with polatuzumab vedotin shows high response rates and durable remissions in heavily pretreated relapsed/refractory large B-cell lymphoma (LBCL).

A recent study reveals that daily intake of vitamin B3 significantly reduces lung inflammation in individuals with Chronic Obstructive Pulmonary Disease (COPD).

A novel drug candidate, NK2R, has demonstrated weight loss effects in preclinical studies by targeting appetite and increasing calorie burning.